EIPA hydrochloride

EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC 50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na + /H + -exchanger 3 ( NHE3 ). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer , colon carcinoma, pancreatic carcinoma. In Vitro EIPA hydrochloride (100 μM, 30 min) suppresses TRPP3-mediated Ca 2+ uptake in X. laevis oocytes. EIPA hydrochloride (10-100 μM) reversibly inhibits the basal Na + current (IC 50 : 19.5 μM). EIPA hydrochloride (300 μM, 6h) enhances autophagy through NHE3 (Na + /H + -exchanger 3) in IEC-18 cells. EIPA hydrochloride (20 μM, 2 h) blocks macropinocytosis-mediated uptake of CA-PZ massively entry in HT-29 cells and MIA PaCa-2 cells. EIPA hydrochloride (30 μM, 3h) attenuates Zinc/Kainate toxicity by decreasing Zn 2+ entry in cerebellar granule neurons . EIPA hydrochloride (5-100 μM, 48h) suppresses proliferation of MKN28 cells through up-regulation of p21 expression . EIPA hydrochloride (3 μM, 6 h) inhibits the LPS-induced increase in the level of COX-2 protein. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay Cell Line: MKN28 cells Concentration: 5, 10, 25, 50, and 100 μM Incubation Time: 48 h Result: Inhibited cell proliferation in a dose- and time-dependent manner. Western Blot AnalysisCell Line: IEC-18 cells Concentration: 300 μM Incubation Time: 6 h Result: Increased total LC3-II protein levels and P62 flux. Increased ATG5, 7, 12 and P62 expression. In Vivo EIPA hydrochloride (Intravenous injection, 1 mg/kg) dose-dependently attenuates the I/R (Ischemia/reperfusion)-induced renal dysfunction in ddY strain mice . EIPA hydrochloride (oral administration, 10 mg/kg) inhibits LPS-induced inflammation in air pouch-type LPS-induced inflammation model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ddY strain mice Dosage: 1 mg/kg Administration: Intravenous injection Result: Attenuated histologic renal damage, and imprved the I/R-induced increases in renal ET-1 contents. Animal Model: Air pouch-type LPS-induced inflammation model Dosage: 10 mg/kg Administration: Oral administration Result: Inhibited the LPS-induced infiltration of leukocytes into the pouch. Inhibited the amount of PGE2 in the pouch fluid.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet